Filing Analysis
Ovid Therapeutics Inc. filed an 8-K to announce its second quarter 2026 financial results and provide a general business update via press release.
📋 Key Facts
- Report date: August 13, 2026
- The filing covers the announcement of Q2 2026 financial results.
- The company issued a press release (Exhibit 99.1) containing business updates.
- Chief Financial Officer Charles Carter signed the report.
Ovid Therapeutics announced the mutual departure of Jeffrey Rona from his roles as CFO, PFO, PAO, and Secretary, effective July 6, 2026. Charles Carter has been appointed as the new CFO to succeed him.
🚩 Red Flags
- Departure of multiple key roles (CFO, PFO, PAO, Secretary) simultaneously.
- Significant severance package for the departing officer including a full year's salary and bonus.
- Extended consulting arrangement through 2027 suggests a prolonged transition or dependency on the outgoing officer.
📋 Key Facts
- Jeffrey Rona's separation date is July 6, 2026.
- Charles Carter (formerly SVP of Finance and Financial Planning) appointed as CFO, effective July 6, 2026.
- Mr. Rona will receive 12 months of base salary in monthly installments, a prorated 2026 bonus, and 12 months of COBRA benefits.
- The Company entered into a consulting agreement with Mr. Rona to provide advisory services through December 31, 2027.
- Mr. Carter's compensation includes a $460,000 base salary and an RSU grant of 50,000 shares vesting in two equal annual installments starting July 2027.
Ovid Therapeutics Inc. reported the results of its annual meeting of stockholders held on June 10, 2026. Stockholders elected a director, approved executive compensation on an advisory basis, and ratified the appointment of KPMG LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 10, 2026.
- Quorum achieved with 130,958,928 shares (75.7%) present or represented by proxy out of 173,037,131 outstanding shares.
- Jeremy M. Levin was elected as a director for a three-year term.
- Executive compensation was approved on an advisory basis (84.5M votes 'For').
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Ovid Therapeutics Inc. announced the appointment of Anna Greka, M.D., Ph.D., as a Class III director effective June 15, 2026. This appointment increases the total size of the Board of Directors to seven members.
📋 Key Facts
- Anna Greka, M.D., Ph.D., appointed as Class III director with a term expiring at the 2029 annual meeting.
- Effective date of appointment is June 15, 2026.
- Dr. Greka will serve on the Compensation Committee and the Science and Technology Committee.
- Dr. Greka is a Professor of Medicine at Harvard Medical School and holds leadership roles at the Broad Institute of MIT and Harvard.
- Board size increased to seven directors.
Ovid Therapeutics Inc. reported its first quarter 2026 financial results and provided business updates on May 12, 2026. The information was furnished as part of a routine quarterly earnings announcement.
📋 Key Facts
- The filing was made on May 12, 2026, covering the period ending March 31, 2026.
- The company furnished a press release as Exhibit 99.1 detailing Q1 2026 financial results.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- Jeffrey Rona, Chief Business and Financial Officer, signed the report.
Ovid Therapeutics announced the full exercise of Series A Warrants from its October 2025 private placement, resulting in approximately $53.9 million in gross proceeds. The transaction involved the issuance of 33,597,860 common shares and 4,883,464 pre-funded warrants.
🚩 Red Flags
- Significant equity dilution resulting from the issuance of over 38 million shares/equivalents.
📋 Key Facts
- Series A Warrants expired on April 17, 2026.
- Total underlying shares involved were 38,481,325.
- Common stock exercise price was $1.40 per share.
- Pre-funded warrants exercise price was $1.399 per share.
- Total gross proceeds to the Company amounted to approximately $53.9 million.
- The warrants originated from a private placement conducted in October 2025.
Ovid Therapeutics entered into a $60 million PIPE financing agreement to issue common stock and pre-funded warrants. The proceeds are earmarked for the clinical expansion of its OV329 program and general research and development.
🚩 Red Flags
- Significant shareholder dilution resulting from the issuance of approximately 29.8 million shares/warrants.
- The use of a PIPE (Private Investment in Public Equity) structure rather than a traditional public offering.
📋 Key Facts
- The PIPE financing involves the sale of 19,154,321 shares of common stock and 10,701,710 pre-funded warrants.
- Gross proceeds are expected to be $60.0 million before fees and expenses.
- The purchase price is $2.01 per share and $2.009 per pre-funded warrant (with a $0.001 exercise price).
- Funds will support the expansion of OV329 (a GABA-AT inhibitor) into tuberous sclerosis complex and infantile spasms indications.
- The company also reported Q4 and full year 2025 financial results and Phase 1 clearance for OV4071.
Ovid Therapeutics Inc. issued an 8-K to announce the results from its Phase 1 study of OV350 via a press release.
📋 Key Facts
- The filing is related to clinical trial results for the drug candidate OV350.
- The event reported is a Phase 1 study result announcement.
- Report date: December 18, 2025.
Ovid Therapeutics held a special meeting of stockholders on December 11, 2025, where shareholders approved three major proposals. These include a massive increase in authorized common stock and the conversion/exercise of various preferred stock and warrants to comply with Nasdaq listing rules.
🚩 Red Flags
- Significant dilution potential: Increasing authorized shares from 125M to 315M represents a massive expansion of the capital structure.
- Related-party transaction: Shareholders approved the issuance of securities directly to CEO Jeremy Levin (Proposal 3).
- Nasdaq compliance issues: The need for shareholder approval under Rules 5635(c) and 5635(d) indicates potential regulatory hurdles regarding officer compensation and large-scale share issuances.
📋 Key Facts
- Stockholders approved increasing authorized Common Stock from 125,000,000 to 315,000,000 shares (Proposal 1).
- Approval granted for the conversion of Series B Preferred Stock and exercise of Series A/B Warrants to comply with Nasdaq Listing Rule 5635(d) (Proposal 2).
- Stockholders approved the issuance of securities to CEO Jeremy Levin in accordance with Nasdaq Listing Rule 5635(c) (Proposal 3).
- Quorum was established by 38,044,680 shares (53.42% of outstanding common stock) present at the meeting.
- The filing follows a definitive proxy statement filed on November 7, 2025.
Ovid Therapeutics announced a leadership succession plan effective January 1, 2026. Current CEO Dr. Jeremy M. Levin will transition to Executive Chairman, and Margaret 'Meg' Alexander (currently President and COO) will be appointed as the new CEO.
🚩 Red Flags
- Executive leadership turnover (CEO succession) can introduce strategic uncertainty during the transition period.
📋 Key Facts
- Effective January 1, 2026, Margaret 'Meg' Alexander will become CEO and a Class II Board member.
- Dr. Jeremy M. Levin will transition from CEO to Executive Chairman on January 1, 2026.
- Alexander's new compensation includes a $625,000 base salary and a target bonus of 55%.
- Alexander will be granted stock options for 890,000 shares of common stock with a 10-year term.
- Levin's transition to Executive Chairman involves a three-year employment term with a $430,000 base salary and a 50% target bonus.
Ovid Therapeutics entered into a significant PIPE financing agreement to issue Series B convertible preferred stock and warrants, aiming for total gross proceeds of up to $175.1 million. The deal includes heavy dilution potential due to the high conversion ratio of the preferred stock.
🚩 Red Flags
- Extreme Dilution Risk: The Series B Preferred Stock converts at a 1,000:1 ratio, potentially adding 57.7 million shares to the float.
- Significant Overhang: Combined with warrants, the total potential new common stock issuance is massive relative to current micro-cap scale.
- Related Party Transaction: The Company's CEO is an investor in this PIPE financing.
- Complex Conversion Terms: Conversion is subject to stockholder approval and specific beneficial ownership limitations (19.99% cap).
📋 Key Facts
- Entered into a Securities Purchase Agreement on October 2, 2025.
- Total expected gross proceeds: Up to $175.1 million (initial closing ~$80.8 million).
- Issuance of 57,722 shares of Series B Convertible Preferred Stock.
- Series B Preferred Stock converts into an aggregate of 57,722,000 shares of Common Stock (1,000:1 ratio) subject to stockholder approval.
- Warrants include Series A Warrants for up to 38,481,325 shares and Series B Warrants for 28,861,000 shares.
- The CEO is participating in the transaction as one of the Investors.
- Warrant exercise price: $1.40 per share.
Ovid Therapeutics Inc. has received formal notification from Nasdaq confirming it has regained compliance with the minimum bid price requirement of $1.00 per share. The compliance matter regarding Listing Rule 5550(a)(2) is now considered closed.
🚩 Red Flags
- Historical non-compliance with Nasdaq's minimum bid price requirement indicates past extreme volatility or significant downward pressure on share price.
📋 Key Facts
- Nasdaq confirmed Ovid Therapeutics Inc. regained compliance with Nasdaq Listing Rule 5550(a)(2).
- The rule requires listed companies to maintain a minimum bid price of at least $1.00 per share.
- The notification was received on September 11, 2025.
- Nasdaq has declared the compliance matter closed.
Ovid Therapeutics has failed to regain compliance with Nasdaq's minimum bid price requirement ($1.00) within the initial 180-day period. However, the company has been granted a transfer to the Nasdaq Capital Market and an additional 180-day extension until February 9, 2026, to achieve compliance.
🚩 Red Flags
- Failure to meet minimum bid price requirement within the first grace period.
- Explicit mention of a potential reverse stock split to avoid delisting.
- Downgrade/Transfer from Nasdaq Global Select Market to Nasdaq Capital Market.
- Risk of total delisting if compliance is not met by February 9, 2026.
📋 Key Facts
- The company failed to meet the $1.00 minimum closing bid price requirement by the initial deadline of August 11, 2025.
- Nasdaq approved an application to transfer the listing from the Global Select Market to the Nasdaq Capital Market.
- A second compliance period has been granted, extending the deadline to February 9, 2026.
- The stock will trade under the same symbol 'OVID' on the Nasdaq Capital Market starting August 14, 2025.
- Management explicitly mentioned a reverse stock split as a potential option to regain compliance.
Ovid Therapeutics Inc. held its annual meeting of stockholders on July 9, 2025, where shareholders approved a series of alternate amendments to the Certificate of Incorporation. Most notably, shareholders authorized the Board to implement a reverse stock split in a range of 1-for-10 to 1-for-40.
🚩 Red Flags
- Approval of a significant reverse stock split (up to 1-for-40) is often used to maintain Nasdaq listing compliance or improve share price perception.
- The inclusion of a high-ratio reverse split in an annual meeting agenda typically signals potential liquidity or minimum bid price concerns.
📋 Key Facts
- Annual Meeting held on July 9, 2025; Quorum reached with 78.74% of shares represented (55,992,587 shares).
- Proposal 1: Election of directors Kevin Fitzgerald and Bart Friedman for three-year terms.
- Proposal 2: Advisory approval of executive compensation (Say-on-Pay) was passed.
- Proposal 3: Ratification of KPMG LLP as independent auditors for fiscal year ending Dec 31, 2025.
- Proposal 4: Approval of a reverse stock split with a ratio between 1-for-10 and 1-for-40, at the Board's discretion.
Ovid Therapeutics entered into an amendment to its Exclusive Patent License Agreement with Immedica Pharma, AB. As part of the deal, Immedica purchased Ovid's ongoing royalty obligations for $7.0 million in cash.
🚩 Red Flags
- Complexity of multi-party licensing (Ovid, Marinus/Immedica) can lead to legal or royalty disputes if not clearly defined in the full text.
📋 Key Facts
- Effective Date: June 23, 2025
- Immedica Pharma, AB purchased existing royalty obligations for $7.0 million in cash.
- Payment is due within 10 business days following the effective date.
- The amendment involves rights related to ganaxolone for CDKL5 deficiency disorder in the US and Europe.
- A second amendment is expected within six months to expand field, territory, and patent coverage.
Ovid Therapeutics Inc. filed an 8-K to announce its first quarter 2025 financial results and a general business update via press release.
📋 Key Facts
- Report date: May 13, 2025
- Subject matter: Q1 2025 Financial Results and Business Update
- The filing includes Exhibit 99.1 (Press Release) which contains the detailed financial data.
- Signed by Jeffrey Rona, Chief Business and Financial Officer.
Ovid Therapeutics Inc. announced the scheduling of its 2025 Annual Meeting of Stockholders for July 9, 2025. The filing serves to notify shareholders of the meeting date and establish deadlines for stockholder proposals and director nominations.
🚩 Red Flags
- Meeting date delay: The filing notes the meeting is being held more than 30 days after the one-year anniversary, requiring this specific disclosure under SEC rules.
📋 Key Facts
- 2025 Annual Meeting of Stockholders scheduled for July 9, 2025.
- Record date for stockholders entitled to vote is May 19, 2025.
- Deadline for submission of qualified stockholder proposals (Rule 14a-8) or director nominations is May 12, 2025.
- The meeting date is being delayed by more than 30 days from the anniversary of the 2024 Annual Meeting.
Ovid Therapeutics Inc. filed an 8-K to announce its business updates and financial results for the fourth quarter and full year of 2024.
📋 Key Facts
- Report date: March 11, 2025
- The filing announces Fourth Quarter and Full Year 2024 Financial Results.
- Includes a press release (Exhibit 99.1) regarding business updates.
Ovid Therapeutics Inc. announced the appointment of Stelios Papadopoulos, Ph.D., to its Board of Directors as a Class I director. Dr. Papadopoulos will also serve on the Audit and Compensation Committees.
📋 Key Facts
- Appointment date: March 1, 2025
- Board size increased from five to six directors
- Dr. Papadopoulos appointed to Audit Committee and Compensation Committee
- Term expires at the Company's 2027 annual meeting of stockholders
- New director compensation includes a $45,000 annual base retainer, a one-time option grant of 90,000 shares, and an annual equity award of 45,000 options (effective Feb 20, 2025)
Ovid Therapeutics received a notification from Nasdaq stating that its common stock has fallen below the minimum $1.00 bid price requirement for 31 consecutive trading days. The company has until August 11, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq (Rule 5450(a)(1))
- Failure to maintain minimum bid price ($1.00)
- Potential necessity for a reverse stock split to regain compliance
- Risk of delisting if compliance is not met by August 2025
📋 Key Facts
- Received notice from Nasdaq on February 10, 2025.
- Deficiency: Average closing bid price below $1.00 for the last 31 consecutive trading days.
- Compliance Deadline: August 11, 2025 (180-day period).
- Requirement to cure: Closing bid price must be at least $1.00 for a minimum of 10 consecutive business days before the deadline.
- Potential remedy mentioned: A reverse stock split may be required to regain compliance if transferring to Nasdaq Capital Market.
Ovid Therapeutics Inc. filed an 8-K to announce its third quarter 2024 financial results and business update via a press release.
📋 Key Facts
- Report date: November 12, 2024
- Subject matter: Third Quarter 2024 Financial Results and Business Update
- The filing includes Exhibit 99.1 containing the full press release
- Signed by Jeffrey Rona, Chief Business and Financial Officer
Ovid Therapeutics Inc. announced the appointment of Margaret 'Meg' Alexander as President and Chief Operating Officer (COO), effective September 9, 2024. Ms. Alexander previously served as the company's Chief Strategy Officer.
📋 Key Facts
- Margaret 'Meg' Alexander appointed to President and COO role effective September 9, 2024.
- Ms. Alexander's annual base salary is $500,000 with a target cash incentive bonus of 45%.
- The Board granted Ms. Alexander a stock option to purchase 140,000 shares at an exercise price of $1.07 per share.
- Options vest over a period starting September 9, 2024: 25% after one year, and the remainder in 36 equal monthly installments.
- Severance package includes 12 months of base salary and 12 months of health insurance premiums in the event of involuntary termination without cause or resignation for good reason.
Ovid Therapeutics Inc. filed an 8-K to announce its second quarter 2024 financial results and business update via a press release.
📋 Key Facts
- Report date: August 13, 2024
- Subject matter: Second Quarter 2024 Financial Results and Business Update
- The filing includes Exhibit 99.1 containing the official press release
Ovid Therapeutics announced a consulting agreement with former General Counsel Thomas Perone following his departure due to a workforce reduction. The agreement facilitates a transition of duties through January 31, 2025.
🚩 Red Flags
- Departure linked to workforce reduction (indicates cost-cutting/restructuring).
📋 Key Facts
- Thomas Perone departed as General Counsel, Chief Compliance Officer, and Corporate Secretary effective July 11, 2024.
- The departure was part of a broader workforce reduction.
- A consulting agreement was entered into on July 30, 2024, to transition duties.
- Consulting period is scheduled to run from the separation date until January 31, 2025.
- Monthly consulting fees are capped at a total maximum of $55,000 for the duration of the agreement.
- Outstanding equity awards for Mr. Perone will continue to vest during the consulting period.
Ovid Therapeutics Inc. issued a press release regarding topline data from a Phase 1 clinical trial for OV888/GV101 Capsule, a potential first-in-class therapy for Cerebral Cavernous Malformations.
📋 Key Facts
- Announcement of topline data from a Phase 1 Clinical Trial on July 1, 2024.
- The trial studied OV888/GV101 Capsule as a potential first-in-class therapy for Cerebral Cavernous Malformations.
- Collaboration involves Graviton Bioscience Corporation.
Ovid Therapeutics is implementing a significant workforce reduction of 43% to extend its cash runway. The restructuring includes the departure of two key executives and an estimated $4.0 million in severance charges.
🚩 Red Flags
- Significant workforce reduction (43% of headcount) indicates aggressive cost-cutting to preserve liquidity.
- Departure of two high-level executives (General Counsel and COO).
- Explicit mention of the need to 'extend its cash runway' suggests limited current capital reserves.
📋 Key Facts
- Workforce reduction of 17 people, representing approximately 43% of total headcount.
- Effective separation date for impacted employees is July 11, 2024.
- One-time severance-related charge estimated at approximately $4.0 million.
- General Counsel/Chief Compliance Officer Thomas Perone and COO Jason Tardio are departing the company.
- Company forecasts cash runway into the first half of 2026, contingent on cost savings from this reduction.
Ovid Therapeutics issued a press release regarding Takeda Pharmaceutical Company Limited's Phase 3 topline study results for soticlestat. The information was provided under Item 7.01 (Regulation FD Disclosure) and is considered 'furnished' rather than 'filed'.
📋 Key Facts
- Reported date: June 17, 2024.
- Subject matter: Takeda Pharmaceutical Company Limited's Phase 3 topline study results for soticlestat.
- The disclosure is categorized as Regulation FD Disclosure (Item 7.01).
- Information is 'furnished' under Section 18 of the Exchange Act, meaning it carries less liability than 'filed' information.
Ovid Therapeutics Inc. held its annual meeting of stockholders on June 6, 2024. The company reported the results of shareholder votes regarding director elections, executive compensation (Say-on-Pay), and the ratification of their independent auditor.
📋 Key Facts
- Annual Meeting held on June 6, 2024.
- Quorum was established with 58,503,813 shares (82.62% of outstanding shares) present or represented by proxy.
- All director nominees (Barbara Duncan and Robert Michael Poole) were elected to three-year terms ending in 2027.
- Shareholders approved executive compensation on an advisory basis.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Ovid Therapeutics Inc. filed an 8-K to announce its first quarter 2024 financial results and a general business update via press release.
📋 Key Facts
- The filing is a standard announcement of Q1 2024 financial results and business updates.
- Report date: May 14, 2024.
- The information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Ovid Therapeutics Inc. filed an 8-K to announce its business update and financial results for the fourth quarter and full year of 2023.
📋 Key Facts
- Report date: March 8, 2024
- The filing announces Business Update, Fourth Quarter and Full Year 2023 Financial Results via press release (Exhibit 99.1).
- The information is furnished rather than filed under Section 18 of the Exchange Act.